| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 17 | 2024 | 858 | 4.510 |
Why?
|
| Laryngeal Neoplasms | 6 | 2016 | 84 | 2.700 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 1534 | 2.670 |
Why?
|
| Prostatic Neoplasms | 19 | 2020 | 1550 | 2.390 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 325 | 1.780 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 669 | 1.640 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 1155 | 1.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2017 | 1985 | 1.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 44 | 0.910 |
Why?
|
| RNA, Untranslated | 1 | 2025 | 114 | 0.900 |
Why?
|
| Gene Expression Profiling | 11 | 2024 | 1757 | 0.890 |
Why?
|
| Chordoma | 3 | 2013 | 21 | 0.880 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 190 | 0.880 |
Why?
|
| Mutation | 6 | 2019 | 5906 | 0.860 |
Why?
|
| Alternative Splicing | 2 | 2019 | 356 | 0.730 |
Why?
|
| Mutation, Missense | 3 | 2015 | 879 | 0.720 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2015 | 60 | 0.700 |
Why?
|
| Transfection | 6 | 2015 | 1077 | 0.670 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2019 | 7 | 0.630 |
Why?
|
| Optic Atrophy | 1 | 2019 | 47 | 0.600 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 960 | 0.570 |
Why?
|
| Skin Abnormalities | 2 | 2014 | 33 | 0.550 |
Why?
|
| Microcephaly | 3 | 2019 | 331 | 0.540 |
Why?
|
| Male | 39 | 2024 | 61443 | 0.520 |
Why?
|
| Cataract | 1 | 2019 | 224 | 0.520 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 59 | 0.510 |
Why?
|
| CHARGE Syndrome | 1 | 2015 | 8 | 0.500 |
Why?
|
| Neoplasms | 2 | 2025 | 2794 | 0.500 |
Why?
|
| Prostate | 3 | 2017 | 436 | 0.500 |
Why?
|
| Up-Regulation | 6 | 2015 | 874 | 0.500 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 19 | 0.490 |
Why?
|
| Centrioles | 1 | 2015 | 13 | 0.490 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 91 | 0.490 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2377 | 0.480 |
Why?
|
| White Coat Hypertension | 1 | 2015 | 10 | 0.480 |
Why?
|
| Usher Syndromes | 1 | 2015 | 10 | 0.480 |
Why?
|
| Saliva | 1 | 2015 | 114 | 0.470 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2018 | 1033 | 0.470 |
Why?
|
| Hypogonadism | 1 | 2019 | 296 | 0.470 |
Why?
|
| Down-Regulation | 6 | 2015 | 692 | 0.470 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 2 | 0.460 |
Why?
|
| Dwarfism | 1 | 2015 | 97 | 0.450 |
Why?
|
| Humans | 49 | 2025 | 125110 | 0.450 |
Why?
|
| DNA Helicases | 1 | 2015 | 236 | 0.440 |
Why?
|
| Prognosis | 6 | 2025 | 4683 | 0.440 |
Why?
|
| Middle Aged | 16 | 2024 | 26676 | 0.430 |
Why?
|
| Ephrin-B1 | 1 | 2013 | 8 | 0.430 |
Why?
|
| Cornea | 1 | 2019 | 658 | 0.430 |
Why?
|
| Foot Deformities | 1 | 2013 | 4 | 0.430 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2020 | 508 | 0.430 |
Why?
|
| Tyrosinemias | 1 | 2013 | 5 | 0.420 |
Why?
|
| Skull Base Neoplasms | 1 | 2013 | 36 | 0.410 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2012 | 13 | 0.410 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 1078 | 0.400 |
Why?
|
| Neutropenia | 1 | 2014 | 196 | 0.400 |
Why?
|
| Cochlea | 1 | 2013 | 87 | 0.390 |
Why?
|
| Lymph Nodes | 1 | 2014 | 378 | 0.390 |
Why?
|
| Case-Control Studies | 6 | 2024 | 3310 | 0.380 |
Why?
|
| Limb Deformities, Congenital | 1 | 2013 | 105 | 0.380 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2012 | 106 | 0.380 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1054 | 0.370 |
Why?
|
| Craniofacial Abnormalities | 1 | 2013 | 239 | 0.370 |
Why?
|
| Lymphocytes | 1 | 2013 | 408 | 0.360 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 144 | 0.360 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 682 | 0.350 |
Why?
|
| Proteins | 1 | 2015 | 1040 | 0.330 |
Why?
|
| Female | 24 | 2024 | 66704 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 503 | 0.320 |
Why?
|
| Pedigree | 4 | 2019 | 1610 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1762 | 0.310 |
Why?
|
| Prostatectomy | 3 | 2020 | 344 | 0.300 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 602 | 0.290 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 2061 | 0.280 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 54 | 0.270 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 3422 | 0.270 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 664 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 426 | 0.270 |
Why?
|
| Adult | 11 | 2024 | 29460 | 0.260 |
Why?
|
| Phenotype | 4 | 2019 | 4270 | 0.260 |
Why?
|
| Turkey | 2 | 2019 | 62 | 0.260 |
Why?
|
| Genes, Dominant | 2 | 2004 | 244 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1294 | 0.250 |
Why?
|
| AC133 Antigen | 2 | 2016 | 36 | 0.240 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 20 | 0.240 |
Why?
|
| Genetic Therapy | 2 | 2014 | 688 | 0.240 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 14 | 0.240 |
Why?
|
| Aged | 8 | 2015 | 19656 | 0.240 |
Why?
|
| Apoptosis | 5 | 2015 | 1819 | 0.230 |
Why?
|
| Adenoviridae | 2 | 2004 | 605 | 0.220 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 70 | 0.210 |
Why?
|
| ROC Curve | 2 | 2015 | 571 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1714 | 0.200 |
Why?
|
| RNA, Long Noncoding | 1 | 2025 | 218 | 0.200 |
Why?
|
| Blotting, Western | 3 | 2015 | 1111 | 0.190 |
Why?
|
| Schizophrenia | 1 | 2024 | 312 | 0.180 |
Why?
|
| Tissue Kallikreins | 1 | 2020 | 7 | 0.180 |
Why?
|
| Disease Progression | 3 | 2015 | 2084 | 0.160 |
Why?
|
| Infant | 7 | 2016 | 12609 | 0.150 |
Why?
|
| INDEL Mutation | 1 | 2019 | 88 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 140 | 0.150 |
Why?
|
| Siblings | 1 | 2019 | 186 | 0.140 |
Why?
|
| Child | 7 | 2019 | 24609 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2016 | 14151 | 0.140 |
Why?
|
| Homozygote | 1 | 2019 | 547 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 19 | 0.130 |
Why?
|
| Melanoma | 1 | 2004 | 943 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 860 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2013 | 802 | 0.130 |
Why?
|
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2015 | 1 | 0.130 |
Why?
|
| Phorbols | 1 | 2015 | 5 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 42 | 0.120 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 60 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2015 | 85 | 0.120 |
Why?
|
| Cell Survival | 4 | 2012 | 820 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 86 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 67 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2015 | 88 | 0.120 |
Why?
|
| RNA Interference | 1 | 2016 | 508 | 0.120 |
Why?
|
| Cell Differentiation | 4 | 2011 | 1910 | 0.110 |
Why?
|
| Cell Division | 4 | 2004 | 780 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 47 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 42 | 0.110 |
Why?
|
| Microarray Analysis | 1 | 2015 | 236 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1339 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 41 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 217 | 0.110 |
Why?
|
| Cell Movement | 2 | 2015 | 854 | 0.110 |
Why?
|
| Retinitis Pigmentosa | 1 | 2015 | 84 | 0.110 |
Why?
|
| Phosphotransferases | 1 | 2014 | 41 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 222 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2015 | 333 | 0.110 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 274 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 808 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 66 | 0.110 |
Why?
|
| Fibroblasts | 2 | 2015 | 887 | 0.110 |
Why?
|
| RNA, Transfer | 1 | 2014 | 73 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 114 | 0.110 |
Why?
|
| Prostatic Hyperplasia | 1 | 2014 | 115 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1704 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6537 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 228 | 0.110 |
Why?
|
| Hearing Loss | 1 | 2015 | 136 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 319 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 810 | 0.110 |
Why?
|
| Oncogenes | 1 | 2014 | 176 | 0.110 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 108 | 0.100 |
Why?
|
| Cutis Laxa | 1 | 2013 | 11 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 2814 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 214 | 0.100 |
Why?
|
| Cell Separation | 1 | 2014 | 230 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 418 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 255 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 365 | 0.100 |
Why?
|
| Karyotype | 1 | 2013 | 27 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 121 | 0.100 |
Why?
|
| Exons | 1 | 2015 | 802 | 0.100 |
Why?
|
| CDC2 Protein Kinase | 2 | 2004 | 34 | 0.100 |
Why?
|
| Hashimoto Disease | 1 | 2013 | 21 | 0.100 |
Why?
|
| Heterozygote | 1 | 2015 | 672 | 0.100 |
Why?
|
| Ichthyosis | 1 | 2012 | 29 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1275 | 0.100 |
Why?
|
| Dermatitis | 1 | 2012 | 26 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 118 | 0.100 |
Why?
|
| Hamartoma | 1 | 2013 | 52 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2006 | 4597 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 625 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 520 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 620 | 0.100 |
Why?
|
| Stem Cells | 2 | 2007 | 710 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 880 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 402 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2014 | 230 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2018 | 4821 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2012 | 162 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2014 | 430 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 45 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 373 | 0.090 |
Why?
|
| Vidarabine | 1 | 2011 | 77 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2014 | 367 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 705 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1395 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1592 | 0.090 |
Why?
|
| Etoposide | 1 | 2011 | 115 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 398 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2717 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 69 | 0.090 |
Why?
|
| Base Sequence | 1 | 2015 | 3109 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 110 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 392 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 101 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 217 | 0.090 |
Why?
|
| Vincristine | 1 | 2011 | 191 | 0.090 |
Why?
|
| Rare Diseases | 1 | 2013 | 191 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 128 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1496 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1390 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 362 | 0.090 |
Why?
|
| Exome | 1 | 2015 | 1034 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3898 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 812 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 327 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 288 | 0.080 |
Why?
|
| Cisplatin | 1 | 2011 | 250 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 396 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 185 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2016 | 1053 | 0.080 |
Why?
|
| Piperazines | 1 | 2011 | 241 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2011 | 350 | 0.080 |
Why?
|
| Family | 1 | 2012 | 562 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3044 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 336 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 703 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 1505 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2006 | 114 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1893 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 375 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 2569 | 0.070 |
Why?
|
| Computational Biology | 1 | 2013 | 819 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1284 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1694 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 70 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 2654 | 0.070 |
Why?
|
| Cartilage | 1 | 2007 | 48 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 734 | 0.070 |
Why?
|
| Adipocytes, Brown | 1 | 2007 | 25 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 27 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 37 | 0.070 |
Why?
|
| Time Factors | 4 | 2006 | 6301 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 51 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 41 | 0.070 |
Why?
|
| Neurites | 1 | 2006 | 42 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2006 | 71 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2527 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 109 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2007 | 155 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2006 | 312 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8275 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 345 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2006 | 801 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 2518 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 232 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 44 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 2603 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 81 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 493 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3014 | 0.050 |
Why?
|
| Oxygen | 1 | 2007 | 556 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 48 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 157 | 0.050 |
Why?
|
| Animals | 8 | 2014 | 34304 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 102 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 91 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2003 | 130 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2001 | 8 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2001 | 18 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 156 | 0.050 |
Why?
|
| Cyclin B | 1 | 2001 | 22 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 96 | 0.050 |
Why?
|
| Chromosomes | 1 | 2001 | 207 | 0.040 |
Why?
|
| Cell Death | 1 | 2001 | 239 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 945 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7221 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 307 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2001 | 420 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 627 | 0.040 |
Why?
|
| Mice | 7 | 2014 | 17740 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3175 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 299 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2014 | 16338 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 1023 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 587 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 37 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Hypertelorism | 1 | 2013 | 11 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 475 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 1119 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 4417 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 780 | 0.020 |
Why?
|
| Craniosynostoses | 1 | 2013 | 132 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 578 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 9056 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2003 | 1640 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 635 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 302 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2007 | 121 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2006 | 3756 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 445 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 35 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2007 | 102 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 95 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 85 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 127 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 79 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2006 | 229 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 125 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 163 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 19414 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2007 | 4408 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 88 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 420 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 348 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 465 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 560 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2003 | 34 | 0.010 |
Why?
|
| Osteopontin | 1 | 2003 | 49 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2003 | 66 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 384 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 241 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 626 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2756 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2001 | 42 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 113 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 408 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 1708 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 690 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2878 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 825 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2001 | 218 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1615 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1685 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 909 | 0.010 |
Why?
|